Grace Therapeutics, INC

Grace Therapeutics announced receipt of FDA meeting minutes regarding GTx-104, outlining a path for NDA resubmission with a dual-source manufacturing strategy.

Grace Therapeutics, Inc. has updated its corporate presentation, detailing progress on its lead drug candidate GTx-104 for aneurysmal subarachnoid hemorrhage (aSAH) and providing an update on its other programs.

Grace Therapeutics announced its fiscal year-end financial results for 2026, reporting a reduced net loss and providing an update on its GTx-104 New Drug Application following a Complete Response Letter from the FDA.

Grace Therapeutics announces the departure of VP of Clinical Operations Carrie DAndrea, who will transition to a consulting role.

Grace Therapeutics, Inc. has updated its corporate presentation, detailing progress on its lead drug candidate GTx-104 for aneurysmal subarachnoid hemorrhage (aSAH) and providing an outlook on other pipeline programs.

Grace Therapeutics announced the FDA issued a Complete Response Letter for its New Drug Application for GTx-104, citing CMC and non-clinical issues.

Grace Therapeutics reports significant progress for its lead drug candidate GTx-104 with FDA NDA acceptance and a PDUFA target date set for April 23, 2026, alongside reduced net losses.

Grace Therapeutics, Inc. filed an amended quarterly report (10-Q/A) to correct the reported number of outstanding common shares as of November 13, 2025.

Grace Therapeutics reported reduced net losses and cash burn, with its lead drug candidate GTx-104 progressing towards FDA approval with a PDUFA date set for April 23, 2026.

Grace Therapeutics, Inc. reported submitting its New Drug Application for lead candidate GTx-104 to the FDA, following positive Phase 3 trial results for aneurysmal subarachnoid hemorrhage.

Grace Therapeutics files an amendment to its Form 10-Q to correct the number of outstanding shares of common stock as of December 31, 2024.

Grace Therapeutics announces positive Phase 3 results for GTx-104 and provides an update on its financial condition for the quarter ended December 31, 2024.

Grace Therapeutics reported a net loss for the fiscal year ended March 31, 2026, and received a Complete Response Letter from the FDA for its GTx-104 drug candidate.

Grace Therapeutics, Inc. announced positive Phase 3 clinical trial results for its lead drug candidate, GTx-104, and plans for an FDA New Drug Application submission in the first half of calendar year 2025, despite reporting continued operating losses and a need for additional capital.

Acasti Pharma prioritizes its lead drug candidate, GTX-104, for aneurysmal subarachnoid hemorrhage, while reporting a reduced net loss for fiscal year 2024.

Grace Therapeutics Director Vimal Kavuru acquired 10,000 stock options with an exercise price of $3.80, vesting through September 2026.

Grace Therapeutics, Inc. Director George Kottayil was granted 10,000 stock options with an exercise price of $3.80, vesting over time.

Grace Therapeutics Director Edward Neugeboren was granted 10,000 stock options with an exercise price of $3.8, vesting over several months.

Grace Therapeutics Director A Brian Davis was granted 10,000 stock options with a $3.8 exercise price, vesting over time.

George Kottayil, a director at Grace Therapeutics, acquired stock options for 10,000 shares at an exercise price of $2.72 on May 9, 2025.

Director Edward Neugeboren of Grace Therapeutics, Inc. reports the acquisition of stock options.

Grace Therapeutics, Inc. has filed definitive additional proxy materials with the SEC.

Grace Therapeutics, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on September 12, 2025, seeking approval for director nominees, executive compensation, and auditor ratification.

Acasti Pharma encourages shareholders to vote on key proposals, including director elections, auditor appointment, executive compensation, and corporate restructuring, before the upcoming Annual and Special Meeting on September 30, 2024.

Acasti Pharma Inc. has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.

ADAR1 Capital Management and Daniel Schneeberger have reported a 9.9% beneficial ownership stake in Grace Therapeutics, Inc. through common stock and warrants.

AIGH Capital Management and affiliated entities report a 4.9% stake in Grace Therapeutics, Inc., primarily through exercisable warrants.

AIGH Capital Management LLC and Orin Hirschman have disclosed a 5.9% beneficial ownership stake in Grace Therapeutics, Inc., holding 907,217 common shares.

ADAR1 Capital Management, ADAR1 Capital Management GP, and Daniel Schneeberger have reported a 9.9% beneficial ownership stake in Grace Therapeutics, Inc. as of September 30, 2025.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in Grace Therapeutics, Inc. as of June 30, 2025.

ADAR1 Capital Management, its general partner, and Daniel Schneeberger have filed an amended Schedule 13G, reaffirming a 9.99% beneficial ownership stake in Grace Therapeutics, Inc., primarily through common stock and warrants.